Which companies overlap with Institut de Recherches Internationales Servier's portfolio?

Top competitors by shared drug class: Alberta Health services, Asahi Kasei Pharma Corporation, Assistance Publique - Hôpitaux de Paris, Astellas Pharma China, Inc., Barnes Retina Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-de-recherches-internationales-servier.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Institut de Recherches Internationales Servier — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut de Recherches Internationales Servier pipeline: 0 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bevacizumab experimental	Bevacizumab experimental	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)	Oncology
AG-120	AG-120	phase 3	IDH1 inhibitor	IDH1 (isocitrate dehydrogenase 1)	Oncology
Free [Per/Ind + Aml]	Free [Per/Ind + Aml]	phase 3	ACE inhibitor and calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type voltage-gated calcium channels	Cardiovascular
Bevacizumab control	Bevacizumab control	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)	Oncology
Temozolomide (TMZ)	Temozolomide (TMZ)	phase 3	Alkylating agent	DNA (O6-guanine methylation)	Oncology
Fixed [Per/Ind/Aml]	Fixed [Per/Ind/Aml]	phase 3	ACE inhibitor / thiazide-like diuretic / calcium channel blocker combination	ACE, sodium-potassium-ATPase, L-type calcium channel	Cardiovascular

Therapeutic area mix

Oncology · 4
Cardiovascular · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alberta Health services · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma China, Inc. · 1 shared drug class
Barnes Retina Institute · 1 shared drug class
Baxter · 1 shared drug class
BeBetter Med Inc · 1 shared drug class
Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut de Recherches Internationales Servier:

Cite this brief

Drug Landscape (2026). Institut de Recherches Internationales Servier — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-de-recherches-internationales-servier. Accessed 2026-05-17.